Abstract
Background Transmission blocking vaccines (TBVs) target sexual develop¬ment of the parasite within the mosquito and aim to prevent transmission of malaria from one individual to another. Antibodies raised against Pfs48/45, Pfs230 Region C, PfHAP2, and Anopheles gambiae Alanyl Aminopeptidase N1 (AgAPN1) proteins reduce transmission i.e. have transmission blocking activity [1-5]. Recombinant simian Adenovirus (AdC63 serotype) and Modified Vaccinia Ankara (MVA) viral vectors have been shown to induce high antibody titres to asexual parasite antigens in animal studies [6].
Highlights
Transmission blocking vaccines (TBVs) target sexual develop¬ment of the parasite within the mosquito and aim to prevent transmission of malaria from one individual to another
Materials and methods Protein sequences for each of the antigens were codon optimised for expression in humans and cloned into shuttle vectors, which were recombined with the parental virus and purified to obtain virus expressing the antigen of interest
Mice were vaccinated with AdC63 (i.m.), sera was taken after 2 weeks, and will be followed by an Modified Vaccinia Ankara (MVA) boost (i.d.) eight weeks after the prime
Summary
Viral vectored transmission blocking vaccines against Plasmodium falciparum Melissa C Kapulu1*, Sumi Biswas[1], Andrew Blagborough[2], Sarah C Gilbert[1], Robert E Sinden[2], Adrian VS Hill[1]. From Parasite to Prevention: Advances in the understanding of malaria Edinburgh, UK. From Parasite to Prevention: Advances in the understanding of malaria Edinburgh, UK. 20-22 October 2010
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
